The actual after-tax cash outlay – or what drug companies really spend on R&D – for each new drug (including failures) according to the DiMasi study is approximately $110 million. (That’s in year 2000 dollars, based on data provided by drug companies.)
http://www.citizen.org/publications/...ct.cfm?ID=7065




Reply With Quote

